Article Text

PDF
Concise report
Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays
  1. Moises Labrador-Horrillo1,
  2. Maria Angeles Martínez2,
  3. Albert Selva-O'Callaghan1,
  4. Ernesto Trallero-Araguás1,
  5. Eva Balada1,
  6. Miquel Vilardell-Tarrés1,
  7. Candido Juarez2
  1. 1Department of Internal Medicine, Vall d’Hebron General Hospital. Universitat Autonoma de Barcelona, Barcelona, Spain
  2. 2Department of Immunology, Sant Pau Hospital. Universitat Autonoma de Barcelona, Barcelona, Spain
  1. Correspondence to Moises Labrador-Horrillo, Department of Internal Medicine, Vall d’Hebron General Hospital, Universitat Autonoma de Barcelona, Barcelona 08035, Spain; mlabrador{at}vhebron.net

Abstract

Background A new myositis-specific autoantibody (anti-p155) directed against transcriptional intermediary factor 1 γ (TIF1γ) has been described as a good marker of cancer-associated myositis (CAM).

Objective To analyse the feasibility of detecting this autoantibody in patient serum samples using new assays with commercially available recombinant TIF1γ.

Methods The study included 90 Spanish patients with dermatomyositis (DM), classified as clinically amyopathic DM, CAM, or DM without cancer. Anti-TIF1γ antibodies were detected by ELISA and immunoblot techniques and compared with anti-p155 antibody detection by protein immunoprecipitation assays with radiolabelled HeLa cells. The κ coefficient was used to compare the agreement between the different tests.

Results Serum samples from 23 (25.6%) and 20 (22.2%) patients with DM recognised TIF1γ by ELISA and immunoblot, respectively. ELISA (κ=0.91) and immunoblot (κ=0.88) showed excellent agreement with immunoprecipitation analysis (anti-p155). Good concordance (κ=0.91) was also seen between ELISA and immunoblot.

Conclusions Excellent agreement was found between anti-p155 detected by immunoprecipitation and anti-TIF1γ detected by ELISA or immunoblot. These data indicate that identification of this autoantibody can be reliably performed in a standard laboratory setting, with potential application in clinical practice for cancer screening in adult patients with DM.

Statistics from Altmetric.com

Footnotes

  • Funding Instituto de Salud Carlos III, Fondo de Investigación Sanitaria PI10/01871.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.